Birth length of at least 50 cm may bump up breast ca risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

An increase in birth length by 2 cm is associated with a 9% increase in breast cancer risk, according to a study reported in PLoS Medicine, online. Isabel dos Santos Silva, MD, PhD, a professor of epidemiology at the London School of Hygiene and Tropical Medicine and colleagues, examined 32 studies involving 22,058 breast cancer cases.

An increase in birth length by 2 cm is associated with a 9% increase in breast cancer risk, according to a study reported in PLoS Medicine, online. Isabel dos Santos Silva, MD, PhD, a professor of epidemiology at the London School of Hygiene and Tropical Medicine and colleagues, examined 32 studies involving 22,058 breast cancer cases.

The researchers found the strongest link between breast cancer and birth size occurred between a length at birth of greater than or equal to 50 cm. In addition to length, a 0.5 kg increment in birth weight, greater than or equal to 3.5 kg, was associated with an estimated 7% increase in the risk of breast cancer (PLoS Med 5: e193, 2008).

“Assuming causality, we estimated that about 5% of all breast cancers in developed countries could be attributable to high birth size,” the researchers wrote. They also said the association between birth size and breast cancer appeared to be largely independent of known risk factors.

“Further research is needed to unravel the biological mechanisms underlying the birth size-breast cancer association,” wrote Dr. Silva’s group.

In an accompanying editorial, Pagona Lagiou, MD, PhD, and Dimitrios Trichopoulos, MD, PhD, both from the epidemiology department at the Harvard School of Public Health in Boston, said while the relative size of the eff ects is small, the individual studies driving the conclusion were of sound epidemiological design. The research relied on objectively documented birth size parameters, allowing little room for bias (PLoS Med 5: e194, 2008).

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content